|
|
|
Volumn 4, Issue 1, 2006, Pages 46-51
|
|
How to design a phase I trial of an anticancer botanical
|
|
Author keywords
Maximum tolerated dose; Medicinal plants; Phase I; Research design
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CYTOTOXIC AGENT;
HERBACEOUS AGENT;
HYPERICUM PERFORATUM EXTRACT;
IRINOTECAN;
ARTICLE;
BREAST CANCER;
CANCER;
CANCER CHEMOTHERAPY;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CYTOTOXICITY;
DOSE RESPONSE;
DRUG EFFECT;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG MEGADOSE;
DRUG SAFETY;
DRUG TOLERABILITY;
HUMAN;
IMMUNITY;
MAXIMUM TOLERATED DOSE;
METHODOLOGY;
OPTIMAL DRUG DOSE;
PHASE 1 CLINICAL TRIAL;
STATISTICAL ANALYSIS;
SURVIVAL;
NEOPLASM;
PHYTOTHERAPY;
REVIEW;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
CLINICAL TRIALS, PHASE I;
HUMANS;
MAXIMUM TOLERATED DOSE;
NEOPLASMS;
PHYTOTHERAPY;
RESEARCH DESIGN;
|
|
EID: 33745961598
PISSN: 1715894X
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (7)
|
|
References (8)
|
